EUVIMEDEUVIMED entdecken
Crossref

Discovery of WEE1 Kinase Inhibitors with Potent Activity against Patient-Derived, Metastatic Colorectal Cancer Organoids

Joel L Syphers iD, Josephine A Wright, Shen Liu, Yi Sing Gee, Fan Gao, Ramesh Mudududdla iD, Da Qing Che, Aeson Chang, Erica K Sloan, Vignesh Narasimhan, Alexander Heriot, Robert G Ramsay iD und 23 weitere

Journal of Medicinal Chemistry · 24.04.2025 · 68 (8) · 8065-8090

DOI: 10.1021/acs.jmedchem.4c02541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.04.2025. Verfasst von Joel L Syphers und 34 weiteren Autor:innen. Beteiligte Einrichtung: Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Organoids, Colorectal Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Gastroenterological Society of Australia, Monash University, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A library of potent WEE1 kinase inhibitors was synthesized based on the discontinued frontrunner clinical candidate AZD1775 (1), many of which were more selective for WEE1 over an undesirable off-target of 1, the kinase PLK1. When tested against patient-derived organoids (PDOs) grown from TP53-mutated colorectal cancer (CRC) peritoneal metastases, 34 (IC50 value of 62 nM) exhibited stronger efficacy than 1 (IC50 value of 120 nM) and the best-in-class clinical candidate ZN-c3 (IC50 value of 127 nM). Against primary CRC PDOs with TP53-WT, 34 significantly enhanced DNA damage, replication stress and apoptosis compared to 1, as well as demonstrated high selectivity over patient-matched normal healthy colon PDOs, highlighting a potential therapeutic window for cancer treatment. Overall, this investigation provides critical insight into several potent WEE1 inhibitors that exhibited exceptional efficacy against CRC PDOs and is the first to utilize a PDO platform to assess their effect on healthy and malignant cell viability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Tyrosine KinasesOrganoidsColorectal NeoplasmsProtein Kinase InhibitorsCell Cycle ProteinsAntineoplastic AgentsDrug DiscoveryHumansApoptosisPyrimidinonesPyrazolesStructure-Activity RelationshipCell Line, TumorDrug Screening Assays, Antitumor

Substanzen

Protein-Tyrosine KinasesWEE1 protein, humanProtein Kinase InhibitorsCell Cycle ProteinsAntineoplastic AgentsPyrimidinonesPyrazolesadavosertib

Autor:innen und Institutionen

  • Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
  • Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia 5000, Australia.
  • Hangzhou Baikai Biopharmaceutical Co., Ltd., Suite A1708-09, Building 2, No. 452, Sixth Avenue, Baiyang Street, Qiantang New Zone, Hangzhou, Zhejiang 310000, China.
  • Lyterian Therapeutics, South San Francisco, California 94080, United States.
  • Zhejiang Jiuzhou Pharmaceutical Co., Ltd., 99 Waisha Road, Taizhou, Zhejiang 318002, China.
  • Department of Colorectal Surgery, Monash Health, Melbourne, Victoria 3800, Australia.

ORCID-Profile: Joel L Syphers, Ramesh Mudududdla, Robert G Ramsay, Tharindie N Silva, Kevin Fenix, Hongfu Lu, Fei Huang, Daniel L Priebbenow, Jonathan B Baell

Förderung

  • Gastroenterological Society of Australia
  • Monash University
  • National Health and Medical Research Council
  • South Australian Health and Medical Research Institute
  • Faculty of Health Science, University of Adelaide

Zitieren

APA

Syphers, J. L., Wright, J. A., Liu, S., Gee, Y. S., Gao, F., Mudududdla, R., Che, D. Q., Chang, A., Sloan, E. K., Narasimhan, V., Heriot, A., Ramsay, R. G., de Nys, R., Silva, T. N., Vrbanac, L., Sammour, T., Lawrence, M. J., Tin, T., Maddern, G. J., …, & Baell, J. B. (2025). Discovery of WEE1 Kinase Inhibitors with Potent Activity against Patient-Derived, Metastatic Colorectal Cancer Organoids. Journal of Medicinal Chemistry, 68(8), 8065-8090. https://doi.org/10.1021/acs.jmedchem.4c02541

Vancouver

Syphers JL, Wright JA, Liu S, Gee YS, Gao F, Mudududdla R, et al. Discovery of WEE1 Kinase Inhibitors with Potent Activity against Patient-Derived, Metastatic Colorectal Cancer Organoids. Journal of Medicinal Chemistry. 2025;68(8):8065-8090. doi:10.1021/acs.jmedchem.4c02541

BibTeX
@article{Syphers2025,
  author = {Syphers, Joel L and Wright, Josephine A and Liu, Shen and Gee, Yi Sing and Gao, Fan and Mudududdla, Ramesh and Che, Da Qing and Chang, Aeson and Sloan, Erica K and Narasimhan, Vignesh and Heriot, Alexander and Ramsay, Robert G and de Nys, Rebekah and Silva, Tharindie N and Vrbanac, Laura and Sammour, Tarik and Lawrence, Matthew J and Tin, Teresa and Maddern, Guy J and Fenix, Kevin and Kaur, Harleen and Barratt, Kate and Kelter, Gerhard and Maier, Armin and Posch, Markus and Lu, Hongfu and Wang, Xiaomin and Zhavoronkov, Alex and Wei, Heping and Huang, Fei and Worthley, Daniel L and Priebbenow, Daniel L and Mukherjee, Siddhartha and Woods, Susan L and Baell, Jonathan B},
  title = {Discovery of WEE1 Kinase Inhibitors with Potent Activity against Patient-Derived, Metastatic Colorectal Cancer Organoids},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {8},
  pages = {8065--8090},
  doi = {10.1021/acs.jmedchem.4c02541}
}
Kostenlos starten →